Votrient (pazopanib)
- Region
- 🇪🇺 EU
- Active substance
- pazopanib
- Company
- Novartis Europharm Limited
- Status
- Authorised
- Therapeutic area
- Carcinoma, Renal Cell
- CHMP opinion
- Mon 14 Jun 2010
- EU approval
- Mon 14 Jun 2010
- Application
- EMEA/H/C/001141
- ATC
- L01XE11
- Official record
- www.ema.europa.eu
Indication
Renal-cell carcinoma (RCC) Votrient is indicated in adults for the first-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease. Soft-tissue sarcoma (STS) Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy. Efficacy and safety have only been established in certain STS histological tumour subtypes.
Regulatory milestones
No milestones recorded in the last year.
Follow Votrient
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.